CCL

Összesen 8 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM130270
Első szerző:Baráth Sándor (biológus)
Cím:Disease Activity-Dependent Siglec-1 Expression on Monocyte Subsets of Patients with Idiopathic Inflammatory Myopathies / Sándor Baráth, Melinda Nagy-Vincze, Zsuzsanna Kun, Dorottya Szinay, Zoltán Griger Jr., Tibor Gábor Béldi, Katalin Szabó, Marianna Száraz-Széles, Zsuzsanna Hevessy, Zoltán Griger
Dátum:2025
ISSN:1661-6596 1422-0067
Megjegyzések:Interferon signature is one of the key pathogenic pathways in idiopathic inflammatory myopathies (IIMs), particularly in dermatomyositis (DM). The aim of this study was to analyze Siglec-1, an interferon-inducible receptor, on different monocyte subsets in IIM subtypes and investigate its association with disease activity measures. Siglec-1 expression was measured by 8-color flow cytometry in 62 IIM patients and 10 healthy controls (HC). Disease activity was assessed using the International Myositis Assessment and Clinical Studies (IMACS) core set measures. Active DM patients exhibited significantly higher Siglec-1 mean fluorescence intensity (MFI) compared to inactive subgroups and HCs in every monocyte subset. Intermediate monocytes displayed the highest Siglec-1 expression across all groups and the strongest associations between disease activity markers. Siglec-1 expression on monocyte subsets was strongly associated with global, extramuscular global, constitutional, cutaneous, muscular, and gastrointestinal activity measures, but not with pulmonary, skeletal, and cardiac activities in the DM population. The best indicator of DM global disease activity among the examined biomarkers was Siglec-1 MFI on intermediate monocytes. Siglec-1 on intermediate monocytes correlates strongly with organ-specific clinical and biochemical markers of disease activity; therefore, it is a candidate biomarker for monitoring IIM disease activity. Siglec-1 could be useful in patient selection for interferon-targeted treatments.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
myositis
idiopathic inflammatory myopathies
dermatomyositis
Siglec-1
type-I interferon
biomarker
disease activity
anifrolumab
flow cytometry
Megjelenés:International Journal Of Molecular Sciences. - 26 : 10 (2025), p. 1-17. -
További szerzők:Nagy-Vincze Melinda (1985-) (orvos) Kun Zsuzsanna Szinay Dorottya (1995-) (Orvos) Griger Zoltán Jr. (2005-) Béldi Tibor (1994-) (orvos) Szabó Katalin (1991-) (orvos) Széles Mariann Hevessy Zsuzsanna (1966-) (laboratóriumi szakorvos) Griger Zoltán (1979-) (belgyógyász, allergológus és klinikai immunológus, reumatológus)
Pályázati támogatás:Publikációs Tudománytámogatási Program PTP/0289/2024
Egyéb
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM122758
Első szerző:Béldi Tibor (orvos)
Cím:A tumorasszociált myositisek sajátosságai : szűrési és kezelési szempontok / Béldi Tibor, Nagy-Vincze Melinda, Griger Zoltán
Dátum:2024
Megjegyzések:Tumorasszociált myositisekről (CAM) akkor beszélünk, amennyiben az idiopathiás inflammathoricus myopathia (IIM) diagnosztizálásától számított +/- 3 éven belül felismerésre kerül valamilyen rosszindulatú daganat. Ismert az irodalomból, hogy bizonyos myositis altípusok, myositis specifikus autoantitestek (MSA) vagy klinikai jellemzők megléte alapján igen fokozott a malignitás kockázata. A CAM-esetek túlélése emellett rossz, ugyanakkor eddig nem volt egyértelmű, konszenzuson alapuló iránymutatás ezen esetek szűrésére és kezelésére. Az utóbbi időben számos új eredmény jelent meg az irodalomban, melyek segítségével megállapítható a tumorok előfordulásának rizikója (magas, közepes, alacsony), és ennek ismeretében többféle szintű szűrési algoritmusokat lehet végezni, amely nagyban segíti és standardizálja a CAM diagnózisát és későbbi kezelését is. Jelen munkánk célja volt a legfrissebb releváns irodalmi adatok ismeretében egy átfogó összefoglaló írása a CAM epidemiológiájáról, pathomechanizmusáról, a rizikóstratifikációról, a szűrési és terápiás lehetőségekről. Ezzel megkönnyíthető a hazai myositises betegellátásban részt vevő orvosok (reumatológusok, immunológusok, bőrgyógyászok, onkológusok) munkája és nőhet a CAM-es betegek túlélése és életminősége.
Tárgyszavak:Orvostudományok Klinikai orvostudományok magyar nyelvű folyóiratközlemény hazai lapban
folyóiratcikk
idiopathiás inflammathoricus myopathiák
malignitás
tumorszűrés
pathomechanizmus
epidemiológia
Megjelenés:Immunológiai Szemle. - 16 : 2 (2024), p. 39-45. -
További szerzők:Nagy-Vincze Melinda (1985-) (orvos) Griger Zoltán (1979-) (belgyógyász, allergológus és klinikai immunológus, reumatológus)
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
Borító:

3.

001-es BibID:BIBFORM103399
035-os BibID:(Scopus)85149171419 (WoS)000952863200010
Első szerző:Béldi Tibor (orvos)
Cím:The effect of COVID-19 pandemic on idiopathic inflammatory myositis patients : a single centre experience / Béldi Tibor, Vincze Anett, Miltényi-Szabó Balázs, Varga Zsófia, Szabó Katalin, Griger Zoltán, Nagy-Vincze Melinda
Dátum:2023
ISSN:0392-856X 1593-098X
Megjegyzések:Objectives: Pandemic caused by coronavirus disease (COVID-19) determines the life of clinicians and patients since 2 years. We have a lot of information about disease course, treatment and protection against virus, but less on the prognosis of infection in patients with idiopathic inflammatory myopathies (IIM). Also few data are available on triggered humoral response and side effects after vaccination. Methods: Our goal was to assess by a retrospective cross-sectional study the above data in our cohort (176 IIM patients) by identifying COVID-19 positive patients and follow disease course. Incidence and complications of vaccination were determined by questionnaires. 101 patients volunteered for complex blood test. Results: By June 1st, 2021 significantly higher incidence of COVID 19 infections (34.7%) were identified comparing to the national prevalence (8.2%). A third of these infections occurred asymptomatically or mild. Patients requiring hospitalisation had a significantly longer disease duration and a higher incidence of anti-Jo-1 antibody. All patients infected by COVID-19 became seropositive regardless the immunosuppressive therapy or symptoms severity. 54.3% of the patients received anti-COVID-19 vaccine. 72.3% of patients became seropositive after vaccination. Higher antibody titer against spike protein was detected after Pfizer-BioNTech vaccination compared to others. Patients receiving steroid therapy had decreased post-vaccination antibody response compared to those without steroid treatment. No major post-vaccination infection was observed. Conclusions: Based on our results, myositis may be associated with an increased risk of COVID-19 infection. Independent risk factor for hospitalisation are longer disease duration and anti-Jo1 positivity. Anti-SARS-CoV2 vaccines seem safe and tolerable and strongly recommended for that population.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
myositis
interstitial lung disease
COVID infection
vaccination
Megjelenés:Clinical And Experimental Rheumatology. - 41 : 2 (2023), p. 254-260. -
További szerzők:Vincze Anett (1993-) (orvos) Miltényi-Szabó Balázs (1996-) (orvostanhallgató) Varga Zsófia (1992-) (molekuláris biológus) Szabó Katalin (1991-) (orvos) Griger Zoltán (1979-) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Nagy-Vincze Melinda (1985-) (orvos)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

4.

001-es BibID:BIBFORM125984
Első szerző:Nagy-Vincze Melinda (orvos)
Cím:High fetal risk in pregnancies of myositis patients : a Hungarian cohort study / Nagy-Vincze Melinda, Szinay Dorottya, Szabó Katalin, Molnár Deliné Sarolta, Balkay László, Béldi Tibor, Griger Zoltán
Dátum:2024
ISSN:2813-6934
Megjegyzések:Background: Several systemic autoimmune rheumatic diseases may affect both fetal and maternal outcomes during pregnancy. However, little information is available regarding pregnancy outcomes in women with idiopathic inflammatory myopathy. Previously published articles stated that the activity of maternal disease may worsen pregnancy outcomes. A former multicenter study suggested that anti-Jo1 antibody positivity and joint involvement could distinguish a more vulnerable group regarding pregnancy complications. Our aim was to identify prognostic factors among clinical symptoms at disease onset and auto-antibody profiles for identifying a high-risk group for poor pregnancy outcome. Methods: The clinical data of the myositis cohort of the Division of Clinical Immunology, University of Debrecen, Hungary, were reviewed retrospectively. IIM diagnoses were made by Bohan and Peter's criteria or European Alliance of Associations for Rheumatology/American College of Rheumatology (EULAR/ACR) criteria. Disease activity was evaluated based on physician opinion. Gynecological definitions were used to evaluate fetal outcomes. Results: Reviewing clinical data of overall 763 patients (542 women and 221 men) revealed that 5.2% of female patients had pregnancies in the same time or after myositis onset. Among these, 71.4% of the mothers suffered from polymyositis (PM) and 28.6% suffered from dermatomyositis (DM). Their mean age at the time of myositis diagnosis was 25.28?years, and the average interval between myositis diagnosis and first pregnancy was 55.4?months. Maternal complications included preeclampsia in one case and pregnancy-induced myositis in 25% of cases. All cases of pregnancy-induced myositis improved after immunosuppressive treatment. Twenty-eight patients reported 60 pregnancies overall, with multiple pregnancies occurring in 57% of cases. Early or late fetal loss was detected in 41.7% of the pregnancies, and stillbirth occurred in 18.3% of deliveries. Although late fetal loss was observed mainly due to placental insufficiency in patients with anti-Jo1 positivity and complications seemed more frequent in PM cases, logistic regression analysis only confirmed that multiple pregnancies could be an independent risk factor for fetal (p?=?0.0112) and interstitial lung disease of maternal complications (p?=?0.02). Conclusion: Internal organ involvement and the number of pregnancies could influence pregnancy outcomes in myositis patients. Patients' family planning should be well organized and counseled by myositis experts. Prospective, multicenter collaborations are needed to precisely identify high-risk groups and state managing guidelines.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
polymyositis
dermatomyositis
pregnancy
outcome
miscarriages
internal organ involvement
Megjelenés:Frontiers in Lupus. - 2 (2024), p. 1-7. -
További szerzők:Szinay Dorottya (1995-) (Orvos) Szabó Katalin (1991-) (orvos) Deliné Molnár Sarolta (1990-) (patológus) Balkay László (1963-) (biofizikus) Béldi Tibor (1994-) (orvos) Griger Zoltán (1979-) (belgyógyász, allergológus és klinikai immunológus, reumatológus)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

5.

001-es BibID:BIBFORM109477
035-os BibID:(Scopus)85150818434 (WoS)000949012200001
Első szerző:Nagy-Vincze Melinda (orvos)
Cím:Incidence, features and outcome of disease relapse after Covid-19 vaccination in patients with idiopathic inflammatory myopathies / Nagy-Vincze Melinda, Béldi Tibor, Szabó Katalin, Vincze Anett, Miltényi-Szabó Balázs, Varga Zsófia, Varga József, Griger Zoltán
Dátum:2023
ISSN:0148-639X
Megjegyzések:Introduction/Aims Vaccination against coronavirus disease (COVID-19) is relatively safe in patients with idiopathic inflammatory myopathies (IIM), however, myositis flares following vaccination have been poorly studied. We aimed to evaluate the frequency, features and outcomes of disease relapses in patients with IIM following COVID-19 vaccination. Methods A cohort of 176 IIM patients were interviewed after the 3rd wave of the COVID-19 pandemic and followed prospectively. Relapses were determined using the disease state criteria and the outcome of the flares with myositis response criteria, calculating the total improvement score (TIS). Results A total of 146 (82.9%) patients received a vaccination, 17/146 (11.6%) patients had a relapse within 3 months, and 13/146 (8.9%) patients within one month. The relapse rate of unvaccinated patients was 3.3%. Three months after the post-vaccination relapses, 70.6% of the patients (12/17) achieved an improvement of disease activity (average TIS score: 30?15.81; 7 minor, 5 moderate and 0 major improvements). Six months after flares improvement was detected in 15/17(88.2%) of relapsed patients (average TIS score: 43.1?19.53; 3 minimal, 8 moderate and 4 major). Forward stepwise logistic regression analysis revealed that the active state of myositis at the time of injection (p<0.0001; OR:33; CI:9?120) was significantly associated with the occurrence of a relapse. Discussion A minority of the vaccinated IIM patients had a confirmed disease flare after COVID-19 vaccination and the majority of the relapses improved after individualized treatment. An active disease state at the time of vaccination probably contributes to the increased risk of a post vaccination myositis flare.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Covid-19 vaccination
idiopathic inflammatory myopathies
myositis
relapse
flare
Megjelenés:Muscle & Nerve. - 67 : 5 (2023) p. 371-377. -
További szerzők:Béldi Tibor (1994-) (orvos) Szabó Katalin (1991-) (orvos) Vincze Anett (1993-) (orvos) Miltényi-Szabó Balázs (1996-) (orvostanhallgató) Varga Zsófia (1992-) (PhD hallgató) Varga József (1955-) (fizikus) Griger Zoltán (1979-) (belgyógyász, allergológus és klinikai immunológus, reumatológus)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

6.

001-es BibID:BIBFORM101701
035-os BibID:(WOS)000802856500004 (Scopus)85130364595
Első szerző:Szabó Katalin (orvos)
Cím:Clinical, Serological, and Genetic Characteristics of a Hungarian Myositis-Scleroderma Overlap Cohort / Szabó Katalin, Bodoki Levente, Nagy-Vincze Melinda, Béldi Tibor, Vincze Anett, Zilahi Erika, Varga József, Szűcs Gabriella, Dankó Katalin, Griger Zoltán
Dátum:2022
ISSN:2314-6133 2314-6141
Megjegyzések:Overlap myositis is a distinct subgroup of idiopathic inflammatory myositis (IIM) with various clinical phenotypes. The aim of this study was to determine the clinical, serological, and genetic features of systemic sclerosis (SSc)-IIM overlap patients. It was a retrospective study using clinical database of 39 patients, fulfilling both the criteria of SSc and IIM. 56.4% of the patients had limited cutaneous, 43.6% had diffuse cutaneous SSc, whereas 7.7% of the patients had dermatomyositis and 92.3% polymyositis. The two diseases occurred simultaneously in 58.97%, while 10.26% in myositis and 30.77% in scleroderma were initially diagnosed. The frequencies of organ involvement were interstitial lung disease 71.8%, dysphagia 66.7%, cardiac involvement 41%, pulmonary arterial hypertension (PAH) 30.8%, and renal involvement 12.8%, respectively. The presence of human leukocyte antigen eth HLA THORN - DRB1 * 03 and DQA1 * 051 * 01 alleles were significantly higher in the overlap patients than in healthy controls (82.35% vs. 27.54%; p < 0.0001 and 88.24% vs. 30.16; p < 0.0001). Certain clinical parameters, such as fever at diagnosis (41.67% vs. 7.41%, p = 0.0046), cardiac involvement (83.33% vs. 22.22%, p = 0.0008), subcutaneous calcinosis (41.66 vs. 11.11, p = 0.01146), and claw hand deformity (25% vs. 11.11%, p = 0.00016) were significantly associated with the presence of PAH. Upon comparison, the overlap patients and anti-Jo-1 positive antisynthetase patients showed similarities in terms of genetic results and major clinical features; however, SSc-IIM overlap patients could be distinguished with higher erythrocyte sedimentation rate (ESR) level, more frequent presence of Raynaud's phenomenon (p < 0.0001; OR: 20.00), dysphagia (p < 0.0001; OR: 15.63), and infrequent livedo reticularis (p < 0.01; OR: 0.11). SSc-IIM overlap myositis is a unique group within IIM-s possessing characteristic clinical features.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Biomed Research International. - 2022 (2022), p. 1-9. -
További szerzők:Bodoki Levente (1986-) (PhD hallgató) Nagy-Vincze Melinda (1985-) (orvos) Béldi Tibor (1994-) (orvos) Vincze Anett (1993-) (orvos) Zilahi Erika (1964-) (molekuláris biológus) Varga József (1955-) (fizikus) Szűcs Gabriella (1963-) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Dankó Katalin (1952-2021) (belgyógyász, allergológus és klinikai immunológus) Griger Zoltán (1979-) (belgyógyász, allergológus és klinikai immunológus, reumatológus)
Pályázati támogatás:EFOP-3.6.3-VEKOP-16-2017-00009
EFOP
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

7.

001-es BibID:BIBFORM129928
035-os BibID:(WoS)001496704400001 (Scopus)105006669489
Első szerző:Szinay Dorottya (Orvos)
Cím:Assessment of Efficacy and Safety of Lipid-Lowering Treatment and Its Importance in Risk Assessment and Prevention in a Hungarian Myositis Cohort / Dorottya Szinay, Katalin Szabó, Henrik Molnár, Tibor Béldi, Viktor Bencs, Hajnalka Lőrincz, Mariann Harangi, Zoltán Griger, Melinda Nagy-Vincze
Dátum:2025
ISSN:2077-0383
Megjegyzések:Background: Idiopathic inflammatory myopathies (IIMs), also known as myositis, are systemic autoimmune diseases characterized by chronic inflammation affecting the skin, muscles, and internal organs. Besides traditional risk factors and immune-mediated myocarditis, continuous activity of the immune system increases cardiovascular disease (CVD) risk, meaning that cardiovascular events are the leading causes of mortality in IIM patients. Statins are the most widely used lipid-lowering therapies, which reduce cardiovascular risk, but the fear of adverse muscular events inhibits the frequency of use. Methods: Our aim was to assess the CVD risk in a myositis cohort using the SCORE2 prediction system, carotid artery Doppler ultrasound measurement, and biomarkers; recommend individual lipid-lowering treatment; and follow the efficacy and adverse events of therapy in a 6-month treatment period. Results: The study population (80 IIM patients) was a middle-aged, female-dominant myositis cohort with an average disease duration of 9 years and low median global disease activity. Based on the SCORE2 evaluation, 78.8% of patients had medium/high CVD risk, while 73.13% had asymptomatic carotid plaque. After 6 months of adequate lipid-lowering therapy, 37.5% of patients reached a lower CVD risk category, the biomarker levels of atherosclerosis significantly decreased, and no progression in carotid plaques was detected. None of the patients reported an adverse muscular event or IIM relapse. Conclusions: Our findings proved that the CVD risk of patients with myositis is high, but carefully applied lipid-lowering treatment is the key to effective risk reduction. Risk stratification and the recommendation of preventive treatment are the responsibility of the treating physician.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
idiopathic inflammatory myopathies
cardiovascular disease risk
statin
efficacy
Megjelenés:Journal of Clinical Medicine. - 14 : 10 (2025), p. 1-18. -
További szerzők:Szabó Katalin (1991-) (orvos) Molnár Henrik Béldi Tibor (1994-) (orvos) Bencs Viktor (1995-) (orvos) Lőrincz Hajnalka (1986-) (biológus) Harangi Mariann (1974-) (belgyógyász, endokrinológus) Griger Zoltán (1979-) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Nagy-Vincze Melinda (1985-) (orvos)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

8.

001-es BibID:BIBFORM111641
035-os BibID:(scopus)85160027968
Első szerző:Vincze Anett (orvos)
Cím:Pruritogenic molecules in the skin of patients with dermatomyositis / Vincze Anett, Herczeg-Lisztes Erika, Szabó Katalin, Béldi Tibor Gábor, Nagy-Vincze Melinda, Pór Ágnes, Varga József, Dankó Katalin, Biró Tamás, Tóth Balázs István, Griger Zoltán
Dátum:2023
ISSN:2296-858X
Megjegyzések:Introduction: Pruritus is a common excruciating symptom in systemic autoimmune diseases such as dermatomyositis (DM) but the pathogenesis is not fully understood. We intended to investigate the targeted expression analysis of candidate molecules involved in the development of pruritus in lesional vs. non-lesional skin samples of patients affected with active DM. We looked for correlations between the investigated pruriceptive signaling molecules, disease activity, and itching sensation of DM patients. Methods: Interleukins (IL-33 and IL-6), tumor necrosis factor ? (TNF-?), peroxisome proliferator-activated receptor ? (PPAR-?), and ion channels belonging to the transient receptor potential (TRP) family were analyzed. The expression of TNF-?, PPAR-?, IL-33, IL-6, and TRP channels in lesional DM skin was evaluated by RT-qPCR and immunohistochemistry and was compared with non-lesional DM skin samples. Pruritus, disease activity, and damage of DM were evaluated by the 5-D itch scale and Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), respectively. Statistical analysis was performed with IBM SPSS 28 software. Results: A total of 17 active DM patients participated in the study. We could show that the itching score was positively correlated with the CDASI activity score (Kendall's tau-b = 0.571; p = 0.003). TNF-? gene expression was significantly higher in lesional DM skin than in non-lesional DM skin (p = 0.009) and differed in the subgroups of patients with different itch intensities (p = 0.038). The mRNA expression of lesional IL-6 correlated positively with 5-D itch and CDASI activity score (Kendall's tau-b = 0.585; p = 0.008 and 0.45; p = 0.013, respectively). TRPV4 expressions were positively correlated with CDASI damage score (Kendall's tau-b = 0.626; p < 0.001), but the mRNA expressions of the TRP family, PPAR-?, IL-6, and IL-33 were not different in lesional and non-lesional samples. Immunohistochemistry analysis did not find significant alterations in the expressions of TNF-?, PPAR-?, IL-6, and IL-33 in lesional and non-lesional regions. Discussion: Our results argue that cutaneous disease activity, TNF-?, and IL-6 might play a central role in DM-associated itch, while TRPV4 plays a central role in tissue regeneration.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
dermatomyositis
inflammatory myopathies
itch
pruritus
TRP channels
TNF-α
IL-6
Megjelenés:Frontiers in Medicine. - 10 (2023), p. 1168359. -
További szerzők:Lisztes Erika (1986-) (élettanász) Szabó Katalin (1991-) (orvos) Béldi Tibor (1994-) (orvos) Nagy-Vincze Melinda (1985-) (orvos) Pór Ágnes Varga József (1955-) (fizikus) Dankó Katalin (1952-2021) (belgyógyász, allergológus és klinikai immunológus) Bíró Tamás (1968-) (élettanász) Tóth István Balázs (1978-) (élettanász) Griger Zoltán (1979-) (belgyógyász, allergológus és klinikai immunológus, reumatológus)
Pályázati támogatás:134791
OTKA
120187
OTKA
EFOP-3.6.3-VEKOP-16-2017-00009
EFOP
Bolyai János Kutatási Ösztöndíj
Egyéb
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1 
Corvina könyvtári katalógus v10.11.18-SNAPSHOT © 2024 Monguz kft. Minden jog fenntartva.